Featured Research

from universities, journals, and other organizations

Drug That Chokes Off Tumor Blood Vessels Offers New Hope To Lung Cancer Patients

Date:
December 14, 2006
Source:
UT Southwestern Medical Center
Summary:
Patients suffering from the most common type of lung cancer experienced a 20-percent improvement in overall survival in a national clinical trial of a drug that chokes off the blood vessels nourishing tumors, a multicenter study has found.

Dr. Joan Schiller, chief of hematology/oncology, has found that patients with the most common type of lung cancer experienced a 20-percent improvement in survival by using a drug that chokes off the blood vessels nourishing tumors.
Credit: UT Southwestern Medical Center

Patients suffering from the most common type of lung cancer experienced a 20-percent improvement in overall survival in a national clinical trial of a drug that chokes off the blood vessels nourishing tumors, a multicenter study has found.

Dr. Joan Schiller, chief of hematology/oncology at UT Southwestern Medical Center, said: "This is great news for lung cancer patients -- they live longer, and the side effects from Avastin are unlike those of conventional chemotherapy. For example, Avastin does not cause hair loss, nausea, or vomiting."

Results of the Phase III trial involving 878 patients that was conducted by the Eastern Cooperative Oncology Group are reported in the Dec. 14 issue of the New England Journal of Medicine. The publication of the study comes two months after the Food and Drug Administration approved the drug bevacizumab, known under the trademark Avastin, as a first-line treatment for patients with inoperable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer. The FDA approval was based on the findings of the study.

The results of the trial showed that patients who received Avastin along with the conventional chemotherapy drugs paclitaxel and carboplatin had a 35-percent chance of responding to the treatment, compared to 15 percent for patients who received chemotherapy alone.

Dr. Schiller is chairwoman of the Lung Cancer Committee for the Eastern Cooperative Oncology Group, which designed and conducted the study.

"Twenty years ago, we thought no treatment could help patients with advanced lung cancer," said Dr. Schiller, deputy director of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern. "Ten years ago, we found that chemotherapy could improve survival of these patients. Now, we are finding out that this very unique drug called Avastin can also help improve survival even more. Avastin is the first of this very exciting family of drugs to be approved for lung cancer, and there are several other drugs of this type under development which may prove to work even better."

The drugs in the class that includes Avastin are called anti-angiogenic therapeutics because they target the numerous small blood vessels supplying tumors with oxygen and nutrients and ensuring their continued growth. Anti-angiogenic drugs target a protein that plays an important role in the formation of new blood vessels in tumors. These drugs are called targeted therapeutics and have far fewer side effects than chemotherapy drugs because they spare healthy tissues and zero in on the cancer cells they seek to destroy.

Dr. Schiller said the researchers found that Avastin, developed by San Francisco-based Genentech, works well in combination with chemotherapy for a number of reasons.

"The reason for this is that the blood vessels in tumors normally do not allow the chemotherapy drugs to diffuse into the tumors well," she said. "In addition to choking off the tumor blood supply, Avastin also makes the remaining blood vessels healthier and enables them to diffuse the chemo drugs into the tumor better."

Dr. Schiller, president of the National Lung Cancer Partnership, an advocacy group of researchers and patients focused on raising awareness and research funds to fight the most lethal form of cancer, has dedicated her career as a medical oncologist to finding a cure for lung cancer.

The groups of patients she recruited for the study in conjunction with several major medical centers were seen by Dr. Schiller during her previous employment as a medical professor and lung cancer director at the University of Wisconsin.

Other researchers participating in the study came from Vanderbilt University, Nashville; Dana-Farber Cancer Institute, Boston; University of Missouri Ellis Fischel Cancer Center, Columbia, Mo.; Johns Hopkins University, Baltimore; University Hospitals of Cleveland; and Mt. Sinai Hospital, Miami.

The research was funded in part by Public Health Service Grants and grants from the National Cancer Institute, National Institutes of Health and the U.S. Department of Health and Human Services.

According to the American Cancer Society, lung cancer will kill an estimated 162,460 people in the United States in 2006 -- 90,330 men and 72,130 women -- and a projected 174,470 new lung cancer cases will be diagnosed.


Story Source:

The above story is based on materials provided by UT Southwestern Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

UT Southwestern Medical Center. "Drug That Chokes Off Tumor Blood Vessels Offers New Hope To Lung Cancer Patients." ScienceDaily. ScienceDaily, 14 December 2006. <www.sciencedaily.com/releases/2006/12/061213175147.htm>.
UT Southwestern Medical Center. (2006, December 14). Drug That Chokes Off Tumor Blood Vessels Offers New Hope To Lung Cancer Patients. ScienceDaily. Retrieved August 23, 2014 from www.sciencedaily.com/releases/2006/12/061213175147.htm
UT Southwestern Medical Center. "Drug That Chokes Off Tumor Blood Vessels Offers New Hope To Lung Cancer Patients." ScienceDaily. www.sciencedaily.com/releases/2006/12/061213175147.htm (accessed August 23, 2014).

Share This




More Health & Medicine News

Saturday, August 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins